SCHEMBL6596113

SCHEMBL6596113

C[Si](C)(C)c1cc2ccccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.48
ADRB2 P07550 1/20 0.48
ASIC3 Q9UHC3 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.48
AGXT P21549 1/20 0.44
MGLL Q99685 1/20 0.44
CA12 O43570 3/20 0.43
CA9 Q16790 3/20 0.43
BCL2L1 Q07817 1/20 0.42
CA2 P00918 2/20 0.41
APP P05067 2/20 0.40
ADRA1D P25100 2/20 0.40
GRM5 P41594 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30444190 0.80 CYP2A6 (0.43) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL19557296 0.80 CYP2A6 (0.43) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL17856939 0.78 CYP2A6 (0.44) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL30444116 0.78 CYP2A6 (0.44) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL15274417 0.77 NPC1 (0.31)
SCHEMBL28514083 0.75 BCL2L1 (0.44) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL31141892 0.75 BCL2L1 (0.44) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL6813386 0.75 APP (0.41) CYP2A6APP
SCHEMBL18271669 0.75 MGLL (0.42) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL1249028 0.74 HSP90AA1 (0.47) CYP2A6APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10836723-B2 Method for synthesizing sodium 2,2,6,6-tetramethylpiperidides KOBELCO ECO-SOLUTIONS CO., LTD. (JP) 2020-11-17 US disclosed
US-9073938-B2 Method for producing aromatic compound NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2015-07-07 US disclosed
US-9073938-B2 Method for producing aromatic compound NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2015-07-07 US disclosed
US-20100137617-A1 METHOD FOR PRODUCING AROMATIC COMPOUND NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2010-06-03 US disclosed
EP-1204660-B1 SEROTONERGIC BENZOTHIOPHENES LILLY CO ELI (US) 2004-10-20 EP disclosed
EP-1204660-A1 SEROTONERGIC BENZOTHIOPHENES ELI LILLY AND COMPANY (US) 2002-05-15 EP disclosed
WO-2001009126-A1 SEROTONERGIC BENZOTHIOPHENES ELI LILLY AND COMPANY (US) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137617-A1 METHOD FOR PRODUCING AROMATIC COMPOUND SCLY, TYR, CBS CYP2A6 342/4885ADRB2 733/4885ASIC3 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.